SG11201806383TA - 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds - Google Patents

6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

Info

Publication number
SG11201806383TA
SG11201806383TA SG11201806383TA SG11201806383TA SG11201806383TA SG 11201806383T A SG11201806383T A SG 11201806383TA SG 11201806383T A SG11201806383T A SG 11201806383TA SG 11201806383T A SG11201806383T A SG 11201806383TA SG 11201806383T A SG11201806383T A SG 11201806383TA
Authority
SG
Singapore
Prior art keywords
international
street
massachusetts
compounds
rule
Prior art date
Application number
SG11201806383TA
Inventor
Thomas Allen Chappie
Nandini Chaturbhai Patel
Patrick Robert Verhoest
Christopher John Helal
Simone Sciabola
Erik Alphie Lachapelle
Travis T Wager
Matthew Merrill Hayward
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201806383TA publication Critical patent/SG11201806383TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11M1111101110101011111 HO 111110111010 11111 10011111011100111110111011# International Bureau (43) International Publication Date .......,./ (10) International Publication Number WO 2017/145013 Al 31 August 2017 (31.08.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind CO7D 519/00 (2006.01) A61P 25/00 (2006.01) AO, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB2017/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: CHAPPIE, Thomas Allen; 59 Hemlock Hill TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Road, Carlisle, Massachusetts 01741 (US). PATEL, DK, LV, Nandini Chaturbhai; 34 Mary Ellen Road, Waban, Mas- EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, sachusetts 02468 (US). VERHOEST, Patrick Robert; 23 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Calvin Road, Newton, Massachusetts 02460 (US). GW, KM, ML, MR, NE, SN, TD, TG). HELAL, Christopher John; 18 Elm Street, Mystic, Con- Declarations under Rule 4.17: necticut 06355 (US). SCIABOLA, Simone; 109 River as to Street, Cambridge, Massachusetts 02139 (US). the identity of the inventor (Rule 4.170) LACHAPELLE, Erik Alphie; 69 Richard Brown Drive, — as to applicant's entitlement to apply for and be granted a Uncasville, Connecticut 06382 (US). WAGER, Travis T.; patent (Rule 4. 1700) 465 Washington Street, Apt. 6, Brookline, Massachusetts as to the applicant's entitlement to claim the priority of the 02446 (US). HAYWARD, Matthew Merrill; 3 Pyrus earlier application (Rule 4.17(iii)) Court, Old Lyme, Connecticut 06371 (US). Published: . (74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, NY 10017 (US). — with international search report (Art. 21(3)) Title: 6,7-DIHYDRO-5H-PYRAZOLO[5,1-B][1,3]0XAZINE-2-CARBOXAMIDE COMPOUNDS = (54) R 1 i 0 NO N N — R 2 en ,—, © ir) ii- / R3 ,-1 IN 1-1 (57) : The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, 0 wherein the substituents R', R 2 , R 3 , and R 'are as defined herein. The invention is also directed to pharmaceutical compositions com- \" prising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
SG11201806383TA 2016-02-23 2017-02-15 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds SG11201806383TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662298657P 2016-02-23 2016-02-23
PCT/IB2017/050844 WO2017145013A1 (en) 2016-02-23 2017-02-15 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

Publications (1)

Publication Number Publication Date
SG11201806383TA true SG11201806383TA (en) 2018-09-27

Family

ID=58347718

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806383TA SG11201806383TA (en) 2016-02-23 2017-02-15 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

Country Status (19)

Country Link
US (2) US10323042B2 (en)
EP (1) EP3419979B1 (en)
JP (1) JP6837072B2 (en)
KR (1) KR102148587B1 (en)
CN (2) CN108699080B (en)
AU (1) AU2017223132B2 (en)
BR (1) BR112018015191B1 (en)
CA (1) CA3015166C (en)
DK (1) DK3419979T3 (en)
ES (1) ES2775674T3 (en)
HU (1) HUE048658T2 (en)
IL (1) IL260536B (en)
MX (1) MX2018010177A (en)
PL (1) PL3419979T3 (en)
PT (1) PT3419979T (en)
RU (1) RU2719599C2 (en)
SG (1) SG11201806383TA (en)
WO (1) WO2017145013A1 (en)
ZA (1) ZA201804619B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3766885T (en) * 2015-06-17 2022-08-09 Pfizer Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2019169326A1 (en) * 2018-03-01 2019-09-06 Board Of Regents, The University Of Texas System Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
TWI839382B (en) 2018-09-10 2024-04-21 日商科研製藥股份有限公司 Novel heterocyclic aromatic amide derivatives and medicines containing the same
CN113490739A (en) * 2019-01-23 2021-10-08 通路治疗公司 Method for treating epilepsy by phosphodiesterase 4(PDE4) inhibition

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239797T1 (en) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd ANTIBODIES TO BETA-AMYLOID OR DERIVATIVES THEREOF AND THEIR USE
DE19709877A1 (en) 1997-03-11 1998-09-17 Bayer Ag 1,5-dihydro-pyrazolo [3,4-d] pyrimidinone derivatives
AU743827B2 (en) 1997-04-09 2002-02-07 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
WO2001062801A2 (en) 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
DE10045112A1 (en) 2000-09-11 2002-03-21 Merck Patent Gmbh Use of indole derivatives for the treatment of diseases of the central nervous system
AU3976402A (en) 2000-11-03 2002-06-03 Proteotech Inc Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
FR2831536A1 (en) 2001-10-26 2003-05-02 Aventis Pharma Sa NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS KDR INHIBITORS
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
US20040132708A1 (en) 2002-05-01 2004-07-08 Wyeth Process for preparing 6-alkylidene penem derivatives
AR039774A1 (en) 2002-05-01 2005-03-02 Wyeth Corp 6-BICYCLE RENTAL-PENEMS AS BETA-LACTAMASAS INHIBITORS
DE10238724A1 (en) 2002-08-23 2004-03-04 Bayer Ag New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
DE10238723A1 (en) 2002-08-23 2004-03-11 Bayer Ag Phenyl substituted pyrazolyprimidines
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
BRPI0410630A (en) 2003-06-19 2006-06-13 Pfizer Prod Inc nk1 antagonist
WO2005025616A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
CA2555071A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
JP2008505085A (en) * 2004-07-01 2008-02-21 メルク　エンド　カムパニー　インコーポレーテッド Mitotic kinesin inhibitor
JP5042828B2 (en) 2004-07-30 2012-10-03 ライナット ニューロサイエンス コーポレイション Antibodies directed against amyloid-beta peptide and methods using the antibodies
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
US20090074775A1 (en) 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
BRPI0609225A2 (en) 2005-05-12 2010-03-09 Pfizer anhydrous crystalline forms of n- [1- (2-ethoxyethyl) -5- (n-ethyl-n-methylamino) -7- (4-methylpyridin-2-yl-amino) -1h-pyrazolo [4,3- d] pyrimidine-3-carbonyl] methanesulfonamide, pharmaceutical composition comprising them and use thereof
CA2608672A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
CA2607499C (en) 2005-06-22 2010-11-30 Pfizer Products Inc. Histamine-3 receptor antagonists
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP2009514846A (en) 2005-11-04 2009-04-09 ファイザー・リミテッド Tetrahydronaphthyridine derivatives
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
MEP23808A (en) 2006-04-21 2010-06-10 Pfizer Prod Inc Pyridine[3,4-b]pyrazinones
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
EP2124933B1 (en) 2007-01-22 2012-10-17 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
TW200951139A (en) * 2008-05-27 2009-12-16 Astrazeneca Ab Chemical compounds 293
TW201102387A (en) * 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
TWI532725B (en) 2010-01-26 2016-05-11 賽諾菲阿凡提斯公司 Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
KR20150119370A (en) * 2013-02-19 2015-10-23 화이자 인코포레이티드 Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
BR112017001334A2 (en) 2014-08-06 2017-11-14 Pfizer imidazopyridazine compounds, their use and pharmaceutical composition comprising them

Also Published As

Publication number Publication date
CN108699080B (en) 2021-05-14
AU2017223132A1 (en) 2018-07-26
WO2017145013A1 (en) 2017-08-31
BR112018015191A2 (en) 2018-12-18
EP3419979B1 (en) 2020-01-29
US10738063B2 (en) 2020-08-11
JP2019505558A (en) 2019-02-28
CA3015166A1 (en) 2018-08-31
HUE048658T2 (en) 2020-07-28
CN113332292A (en) 2021-09-03
DK3419979T3 (en) 2020-03-23
ZA201804619B (en) 2020-12-23
US20190055262A1 (en) 2019-02-21
MX2018010177A (en) 2019-01-21
BR112018015191B1 (en) 2023-10-17
KR20180101568A (en) 2018-09-12
RU2719599C2 (en) 2020-04-21
EP3419979A1 (en) 2019-01-02
RU2018128781A3 (en) 2020-03-24
US10323042B2 (en) 2019-06-18
US20190300546A1 (en) 2019-10-03
PL3419979T3 (en) 2020-06-29
CA3015166C (en) 2021-08-03
AU2017223132B2 (en) 2019-12-05
KR102148587B1 (en) 2020-08-26
PT3419979T (en) 2020-03-26
IL260536B (en) 2020-10-29
ES2775674T3 (en) 2020-07-27
JP6837072B2 (en) 2021-03-03
RU2018128781A (en) 2020-03-24
CN108699080A (en) 2018-10-23

Similar Documents

Publication Publication Date Title
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201903483VA (en) Compositions and methods for treating ezh2-mediated cancer
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201407402TA (en) Carbazole-containing sulfonamides as cryptochrome modulators
SG11201806383TA (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201805649UA (en) Therapeutic anti-cd9 antibody
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders